Soleus Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Soleus Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-764,000	Closed	-$25.9M	–	111
2025 Q4	$25.9M	Buy	764,000 +226,097	+42%	+$7.02M	0.95%	31
2025 Q3	$13.9M	Buy	+537,903	New	+$7.04M	0.7%	36
2020 Q3	–	Sell	-1,888	Closed	-$438K	–	72
2020 Q2	$438K	Buy	+1,888	New	+$292K	0.25%	57

Soleus Capital Management's RAPT Position: Q1 2026 in Review

Soleus Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 764,000 shares — an estimated $25.9M sold.

Soleus Capital Management first reported a position in RAPT in Q2 2020 and held it in 3 quarters. The position peaked at $25.9M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Soleus Capital Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Soleus Capital Management sold 764,000 RAPT Therapeutics shares in Q1 2026, an estimated $25.9M.
Soleus Capital Management first reported a position in RAPT Therapeutics in Q2 2020 and held it in 3 quarters.
Soleus Capital Management's RAPT Therapeutics position peaked at $25.9M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.